Can-Fite BioPharma Ltd. Additional Paid in Capital, Common Stock
Can-Fite BioPharma Ltd. (CANF) had Additional Paid in Capital, Common Stock of $180.65 million as of 2025-12-31, per its 20-F filed 2026-03-26.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-03-26
- 2025-12-31: Additional Paid in Capital, Common Stock $180.65M.
- 2025-06-30: Additional Paid in Capital, Common Stock $174.29M.
- 2024-12-31: Additional Paid in Capital, Common Stock $170.67M.
- 2023-12-31: Additional Paid in Capital, Common Stock $163.60M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2025-12-31 | $180.65M 20-F · filed 2026-03-26 |
| 2025-06-30 | $174.29M 6-K · filed 2025-08-28 |
| 2024-12-31 | $170.67M 20-F · filed 2026-03-26 |
| 2023-12-31 | $163.60M 20-F · filed 2025-04-14 |
| 2022-12-31 | $500.00 20-F · filed 2023-03-30 |